Kazia Therapeutics files provisional patent for strategy to prevent metastatic recurrence in triple-negative breast cancer

• Kazia filed a provisional patent application for a paxalisib-based strategy aimed at preventing metastatic recurrence in high-risk early-stage triple-negative breast cancer.
• Perioperative preclinical model showed adjuvant paxalisib cut residual disease and local recurrence 95% (p<0.0001) and reduced lung metastatic burden 40% (p<0.027).
• Ex vivo patient tumor samples showed paxalisib disrupted 100% of detected circulating tumor cell clusters, supporting expansion into earlier-stage TNBC development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-081982), on July 28, 2026, and is solely responsible for the information contained therein.